Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study

Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study

Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...

Full description

Bibliographic Details
Main Authors: Maria Di Pietrantonio, Lucia Brescini, Jennifer Candi, Morroni Gianluca, Francesco Pallotta, Sara Mazzanti, Paolo Mantini, Bianca Candelaresi, Silvia Olivieri, Francesco Ginevri, Giulia Cesaretti, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Elisabetta Cerutti, Oriana Simonetti, Oscar Cirioni, Marcello Tavio, Andrea Giacometti, Francesco Barchiesi
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Antibiotics
Subjects:
Gram-negative pathogens
multidrug resistance
ceftazidime–avibactam
Online Access:https://www.mdpi.com/2079-6382/11/3/321

Internet

https://www.mdpi.com/2079-6382/11/3/321

Similar Items